北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学药学院  > 药剂学系  > 期刊论文
学科主题: 药学
题名:
Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies
作者: Zhang, Yi-fei2; Wang, Jian-cheng1,2; Bian, Dong-yan2,3; Zhang, Xuan2; Zhang, Qiang1,2
关键词: Combination therapy ; Liposomes ; Targeting ; Combretastatin A-4 ; Doxorubicin
刊名: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
发表日期: 2010-03-01
DOI: 10.1016/j.ejpb.2010.01.002
卷: 74, 期:3, 页:467-473
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: ANTITUMOR EFFICACY ; CELLS ; CHEMOTHERAPY ; PHOSPHATE ; AGENTS ; DRUGS ; ANGIOGENESIS ; VASCULATURE ; COMBINATION ; INDUCTION
英文摘要:

Arg-Gly-Asp (RGD) modified doxorubicin-loaded liposomes could Improve anticancer effect, and vascular disrupting agents (VDAs) could induce a rapid and selective shutdown of the blood vessels of tumors We propose that RGD-modified liposomes for co-encapsulation and sequential release of vascular disrupting agent combretastatin A-4 (CA-4) and cytotoxic agent doxorubicin (Dox) could enhance tumor inhibition responses In this study, we encapsulated Dox and CA-4 in RGD-modified liposomes The release are of Dox was proved to be much slower than that of CA-4 in vitro Flow cytometry and laser confocal scanning microscopy clearly showed that RGD-modification promoted intracellular uptake of liposomal drugs by B16/B16F10 melanoma tumor cells and human umbilical vein endothelial cells (HUVECs) Cytotoxicity assay showed that the IC(50) of RGD-modified liposomes was lower than that of the corresponding unmodified liposomes Therapeutic benefits were examined on B16F10 melanoma tumors subcutaneously glowing in C57BL/6 mice In vivo study demonstrated that RGD-modified liposomes exhibited the most pronounced tumor regression effect when both CA-4 and Dox were co-encapsulated These results suggest that the targeted drug delivery system for co-encapsulation of vascular disrupting agents and anticancer agents may be a promising strategy for cancer treatment (c) 2010 Elsevier B.V All rights reserved

语种: 英语
所属项目编号: 2007AA021811 ; 200703935800 ; 2009z09310-001
项目资助者: National High Technology Research and Development Program of China ; National Basic Research Program of China ; National Key Program of New Drug innovation
WOS记录号: WOS:000276426200007
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53617
Appears in Collections:北京大学药学院_药剂学系_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Dept Pharmaceut, Sch Pharmaceut Sci, Beijing 100083, Peoples R China
2.Peking Univ, Hlth Sci Ctr, State Key Lab Nat & Bromimet Drugs, Beijing 100083, Peoples R China
3.Shen Yang Pharmaceut Univ, Dept Pharmaceut, Shenyang, Peoples R China

Recommended Citation:
Zhang, Yi-fei,Wang, Jian-cheng,Bian, Dong-yan,et al. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies[J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS,2010,74(3):467-473.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhang, Yi-fei]'s Articles
[Wang, Jian-cheng]'s Articles
[Bian, Dong-yan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhang, Yi-fei]‘s Articles
[Wang, Jian-cheng]‘s Articles
[Bian, Dong-yan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace